{
  "doc_id": "26",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "格列喹酮临床应用中国专家共识(2017年版)",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列喹酮临床应用中国专家共识(2017年版)",
          "start_idx": 0,
          "end_idx": 22,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "1",
      "paragraph": "磺脲类胰岛素促泌剂是最早发现并使用最广泛的口服降糖药物，《中国2型糖尿病防治指南(2013)》推荐该类药物为中国2型糖尿病患者降糖治疗的一线备选用药。其中格列喹酮作为二代磺脲类促泌剂，具有良好的降糖作用及安全性，同时兼具肾脏保护作用，获得全球多个权威指南推荐。为进一步指导规范格列喹酮的临床应用，中国50余位知名内分泌代谢领域专家起草、讨论、制订了此专家共识。全文回顾了格列酮相关循证依据，并对药物安全性、有效性、使用人群及使用方法进行了总结和推荐，希望藉此为临床医生提供指导与帮助。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "磺脲类胰岛素促泌剂是最早发现并使用最广泛的口服降糖药物，《中国2型糖尿病防治指南(2013)》推荐该类药物为中国2型糖尿病患者降糖治疗的一线备选用药。",
          "start_idx": 0,
          "end_idx": 75,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "磺脲类胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 9
            },
            {
              "entity_id": "T2",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 21,
              "end_idx": 23
            },
            {
              "entity_id": "T3",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 36
            },
            {
              "entity_id": "T4",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 31,
              "end_idx": 33
            },
            {
              "entity_id": "T5",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 61
            },
            {
              "entity_id": "T6",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 56,
              "end_idx": 58
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R0",
              "head_entity_id": "T2",
              "tail_entity_id": "T1"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R1",
              "head_entity_id": "T1",
              "tail_entity_id": "T3"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R2",
              "head_entity_id": "T4",
              "tail_entity_id": "T3"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R3",
              "head_entity_id": "T6",
              "tail_entity_id": "T5"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "其中格列喹酮作为二代磺脲类促泌剂，具有良好的降糖作用及安全性，同时兼具肾脏保护作用，获得全球多个权威指南推荐。",
          "start_idx": 75,
          "end_idx": 130,
          "entities": [
            {
              "entity_id": "T7",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T8",
              "entity": "磺脲类促泌剂",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 16
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "为进一步指导规范格列喹酮的临床应用，中国50余位知名内分泌代谢领域专家起草、讨论、制订了此专家共识。",
          "start_idx": 130,
          "end_idx": 180,
          "entities": [
            {
              "entity_id": "T9",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "全文回顾了格列酮相关循证依据，并对药物安全性、有效性、使用人群及使用方法进行了总结和推荐，希望藉此为临床医生提供指导与帮助。",
          "start_idx": 180,
          "end_idx": 242,
          "entities": [
            {
              "entity_id": "T10",
              "entity": "格列酮",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "2",
      "paragraph": "一、格列喹酮药代动力学及药理特点",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、格列喹酮药代动力学及药理特点",
          "start_idx": 0,
          "end_idx": 16,
          "entities": [
            {
              "entity_id": "T11",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "3",
      "paragraph": "格列喹酮口服吸收迅速完全，血药浓度2~3h达峰值，平均半衰期1.5h，降糖持续时间为5~8h；其代谢途径95%经粪便排泄，仅5%经肾脏排泄；格列喹酮在肝脏中经羟基化被代谢为大量非活性代谢产物，该代谢过程在肝功能不全患者体内仍可进行，且长期应用亦不影响肝胆疾病患者的肝功能；由于代谢产物无活性，不易产生药物蓄积作用，具有很高的安全性。格列喹酮药代动力学不受血糖、年龄、肾功能的影响。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列喹酮口服吸收迅速完全，血药浓度2~3h达峰值，平均半衰期1.5h，降糖持续时间为5~8h；其代谢途径95%经粪便排泄，仅5%经肾脏排泄；格列喹酮在肝脏中经羟基化被代谢为大量非活性代谢产物，该代谢过程在肝功能不全患者体内仍可进行，且长期应用亦不影响肝胆疾病患者的肝功能；由于代谢产物无活性，不易产生药物蓄积作用，具有很高的安全性。",
          "start_idx": 0,
          "end_idx": 166,
          "entities": [
            {
              "entity_id": "T12",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T13",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 4,
              "end_idx": 6
            },
            {
              "entity_id": "T14",
              "entity": "血药浓度",
              "entity_type": "Pathogenesis",
              "start_idx": 13,
              "end_idx": 17
            },
            {
              "entity_id": "T15",
              "entity": "5~8h",
              "entity_type": "Duration",
              "start_idx": 42,
              "end_idx": 46
            },
            {
              "entity_id": "T16",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 70,
              "end_idx": 74
            },
            {
              "entity_id": "T17",
              "entity": "肝胆疾病",
              "entity_type": "Disease",
              "start_idx": 125,
              "end_idx": 129
            },
            {
              "entity_id": "T18",
              "entity": "肝胆",
              "entity_type": "Anatomy",
              "start_idx": 125,
              "end_idx": 127
            },
            {
              "entity_id": "T20",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 102,
              "end_idx": 107
            },
            {
              "entity_id": "T21",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 102,
              "end_idx": 103
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R4",
              "head_entity_id": "T13",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R5",
              "head_entity_id": "T15",
              "tail_entity_id": "T12"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R6",
              "head_entity_id": "T18",
              "tail_entity_id": "T17"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R7",
              "head_entity_id": "T21",
              "tail_entity_id": "T20"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "格列喹酮药代动力学不受血糖、年龄、肾功能的影响。",
          "start_idx": 166,
          "end_idx": 190,
          "entities": [
            {
              "entity_id": "T19",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T22",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 13
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "4",
      "paragraph": "格列喹酮通过与胰岛β细胞膜上磺脲受体结合促进胰岛素分泌，该结合作用短效可逆，避免了对细胞的持续刺激，降低了发生低血糖的风险。动物试验和床研究均证实，格列喹酮可有效控制餐后血糖(PPG)及血糖波动，促胰岛素分泌的达峰时间为30-~0min，在120~180min后逐渐下降，可见格列喹酮通过促进胰岛素早期时相分泌，较好地模拟生理胰岛素分泌模式，同时降糖作用维持时间适中，可避免下餐前低血糖。研究表明，格列喹酮还可有效改善β细胞功能障碍，改善胰岛素抵抗，增强胰岛素敏感性，其作用机制与增强PPAR靶基因的表达有关，另外，格列喹酮还可通过增加外周组织细胞上胰岛素受体的数目、促进肌细胞葡萄糖摄取等胰外作用协同降低血糖。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列喹酮通过与胰岛β细胞膜上磺脲受体结合促进胰岛素分泌，该结合作用短效可逆，避免了对细胞的持续刺激，降低了发生低血糖的风险。动物试验和床研究均证实，格列喹酮可有效控制餐后血糖(PPG)及血糖波动，促胰岛素分泌的达峰时间为30-~0min，在120~180min后逐渐下降，可见格列喹酮通过促进胰岛素早期时相分泌，较好地模拟生理胰岛素分泌模式，同时降糖作用维持时间适中，可避免下餐前低血糖。",
          "start_idx": 0,
          "end_idx": 194,
          "entities": [
            {
              "entity_id": "T23",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T24",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 55,
              "end_idx": 58
            },
            {
              "entity_id": "T25",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 78
            },
            {
              "entity_id": "T26",
              "entity": "餐后血糖(PPG)",
              "entity_type": "Test_items",
              "start_idx": 83,
              "end_idx": 92
            },
            {
              "entity_id": "T27",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 93,
              "end_idx": 95
            },
            {
              "entity_id": "T28",
              "entity": "波动",
              "entity_type": "Test_Value",
              "start_idx": 95,
              "end_idx": 97
            },
            {
              "entity_id": "T29",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 138,
              "end_idx": 142
            },
            {
              "entity_id": "T30",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 190,
              "end_idx": 193
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R8",
              "head_entity_id": "T24",
              "tail_entity_id": "T23"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R9",
              "head_entity_id": "T30",
              "tail_entity_id": "T29"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "研究表明，格列喹酮还可有效改善β细胞功能障碍，改善胰岛素抵抗，增强胰岛素敏感性，其作用机制与增强PPAR靶基因的表达有关，另外，格列喹酮还可通过增加外周组织细胞上胰岛素受体的数目、促进肌细胞葡萄糖摄取等胰外作用协同降低血糖。",
          "start_idx": 194,
          "end_idx": 306,
          "entities": [
            {
              "entity_id": "T31",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9
            },
            {
              "entity_id": "T32",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 25,
              "end_idx": 30
            },
            {
              "entity_id": "T33",
              "entity": "β细胞功能障碍",
              "entity_type": "Pathogenesis",
              "start_idx": 15,
              "end_idx": 22
            },
            {
              "entity_id": "T34",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 68
            },
            {
              "entity_id": "T35",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 109,
              "end_idx": 111
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "5",
      "paragraph": "格列酮可有效降低尿白蛋白排率泄，并能够抑制NF-κB及其下游炎症因子的激活，抑制糖基化终产物诱导的人肾系膜细胞RANTES的表达和分泌，从而减缓糖尿病肾病的发生发展.。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列酮可有效降低尿白蛋白排率泄，并能够抑制NF-κB及其下游炎症因子的激活，抑制糖基化终产物诱导的人肾系膜细胞RANTES的表达和分泌，从而减缓糖尿病肾病的发生发展.。",
          "start_idx": 0,
          "end_idx": 84,
          "entities": [
            {
              "entity_id": "T36",
              "entity": "格列酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 3
            },
            {
              "entity_id": "T37",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 75
            },
            {
              "entity_id": "T38",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 77
            },
            {
              "entity_id": "T39",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 75,
              "end_idx": 76
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R10",
              "head_entity_id": "T39",
              "tail_entity_id": "T38"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "6",
      "paragraph": "格列喹酮对胰岛β细胞具高度选择性，对心肌细胞、血管平滑肌细胞亲和力弱，因此安全性更高。动物研究显示，格列喹酮具有抗血小板聚集的活性，抗动脉粥样硬化，改善血脂指标，对体重无影响。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列喹酮对胰岛β细胞具高度选择性，对心肌细胞、血管平滑肌细胞亲和力弱，因此安全性更高。动物研究显示，格列喹酮具有抗血小板聚集的活性，抗动脉粥样硬化，改善血脂指标，对体重无影响。",
          "start_idx": 0,
          "end_idx": 88,
          "entities": [
            {
              "entity_id": "T40",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T41",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 54
            },
            {
              "entity_id": "T42",
              "entity": "血脂",
              "entity_type": "Test_items",
              "start_idx": 76,
              "end_idx": 78
            },
            {
              "entity_id": "T43",
              "entity": "动脉粥样硬化",
              "entity_type": "Disease",
              "start_idx": 67,
              "end_idx": 73
            },
            {
              "entity_id": "T44",
              "entity": "动脉",
              "entity_type": "Anatomy",
              "start_idx": 67,
              "end_idx": 69
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R11",
              "head_entity_id": "T41",
              "tail_entity_id": "T43"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R12",
              "head_entity_id": "T42",
              "tail_entity_id": "T43"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R13",
              "head_entity_id": "T44",
              "tail_entity_id": "T43"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "7",
      "paragraph": "二、格列喹酮临床有效性及安全性",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、格列喹酮临床有效性及安全性",
          "start_idx": 0,
          "end_idx": 15,
          "entities": [
            {
              "entity_id": "T45",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "8",
      "paragraph": "1.格列喹酮单药治疗降糖有效性及安全性",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.格列喹酮单药治疗降糖有效性及安全性",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [
            {
              "entity_id": "T46",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "9",
      "paragraph": "我国一项使用格列哇喹4.5年的同回性分析结果显示：格列喹酮单药治疗2型糖尿病，HbA1c降幅1.31%，PPG降幅4.88mmol/L，空腹血糖(FPG)降3幅.88mmol/L。而格列喹酮早期的队列研究结果显示：服用格列哇喹的患者仅有0.13%发生轻度低血糖事件，无严重低血糖发生。可见格列喹酮单药治疗能够全面控制患者血糖，并具有良好的安全性和耐受性。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "我国一项使用格列哇喹4.5年的同回性分析结果显示：格列喹酮单药治疗2型糖尿病，HbA1c降幅1.31%，PPG降幅4.88mmol/L，空腹血糖(FPG)降3幅.88mmol/L。而格列喹酮早期的队列研究结果显示：服用格列哇喹的患者仅有0.13%发生轻度低血糖事件，无严重低血糖发生。",
          "start_idx": 0,
          "end_idx": 142,
          "entities": [
            {
              "entity_id": "T47",
              "entity": "格列哇喹",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T48",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 25,
              "end_idx": 29
            },
            {
              "entity_id": "T49",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38
            },
            {
              "entity_id": "T50",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 33,
              "end_idx": 35
            },
            {
              "entity_id": "T51",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 44
            },
            {
              "entity_id": "T52",
              "entity": "降幅1.31%",
              "entity_type": "Test_Value",
              "start_idx": 44,
              "end_idx": 51
            },
            {
              "entity_id": "T53",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 52,
              "end_idx": 55
            },
            {
              "entity_id": "T54",
              "entity": "降幅4.88mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 55,
              "end_idx": 67
            },
            {
              "entity_id": "T55",
              "entity": "空腹血糖(FPG)",
              "entity_type": "Test_items",
              "start_idx": 68,
              "end_idx": 77
            },
            {
              "entity_id": "T56",
              "entity": "降3幅.88mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 77,
              "end_idx": 89
            },
            {
              "entity_id": "T57",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 91,
              "end_idx": 95
            },
            {
              "entity_id": "T58",
              "entity": "格列哇喹",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 113
            },
            {
              "entity_id": "T59",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 127,
              "end_idx": 130
            },
            {
              "entity_id": "T60",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 136,
              "end_idx": 139
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R14",
              "head_entity_id": "T48",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R15",
              "head_entity_id": "T50",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R16",
              "head_entity_id": "T51",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R17",
              "head_entity_id": "T53",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R18",
              "head_entity_id": "T55",
              "tail_entity_id": "T49"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R19",
              "head_entity_id": "T59",
              "tail_entity_id": "T58"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "可见格列喹酮单药治疗能够全面控制患者血糖，并具有良好的安全性和耐受性。",
          "start_idx": 142,
          "end_idx": 177,
          "entities": [
            {
              "entity_id": "T61",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T62",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 20
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "10",
      "paragraph": "国内一项涉及10家医疗机构、2型糖尿病患者的多中心、自身对照临床试验对格列哇喹的量效关系研究显示，2/3的患者使用30-~20mg/d，若血糖控制不佳可增加剂量，平均剂量为112mg/dl即使剂量增加至270mg/d也无更多低血糖反应发生。提示在一定剂量范围内，格列哇喹降糖作用呈剂量依赖性。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "国内一项涉及10家医疗机构、2型糖尿病患者的多中心、自身对照临床试验对格列哇喹的量效关系研究显示，2/3的患者使用30-~20mg/d，若血糖控制不佳可增加剂量，平均剂量为112mg/dl即使剂量增加至270mg/d也无更多低血糖反应发生。",
          "start_idx": 0,
          "end_idx": 120,
          "entities": [
            {
              "entity_id": "T63",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 14,
              "end_idx": 19
            },
            {
              "entity_id": "T64",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 14,
              "end_idx": 16
            },
            {
              "entity_id": "T65",
              "entity": "格列哇喹",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 39
            },
            {
              "entity_id": "T66",
              "entity": "30-~20mg/d",
              "entity_type": "Amount",
              "start_idx": 57,
              "end_idx": 67
            },
            {
              "entity_id": "T67",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 69,
              "end_idx": 71
            },
            {
              "entity_id": "T68",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 71,
              "end_idx": 75
            },
            {
              "entity_id": "T69",
              "entity": "112mg/dl",
              "entity_type": "Amount",
              "start_idx": 86,
              "end_idx": 94
            },
            {
              "entity_id": "T70",
              "entity": "270mg/d",
              "entity_type": "Amount",
              "start_idx": 101,
              "end_idx": 108
            },
            {
              "entity_id": "T71",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 112,
              "end_idx": 115
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R20",
              "head_entity_id": "T64",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R21",
              "head_entity_id": "T65",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R22",
              "head_entity_id": "T67",
              "tail_entity_id": "T63"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R23",
              "head_entity_id": "T66",
              "tail_entity_id": "T65"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R24",
              "head_entity_id": "T69",
              "tail_entity_id": "T65"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R25",
              "head_entity_id": "T70",
              "tail_entity_id": "T65"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R26",
              "head_entity_id": "T71",
              "tail_entity_id": "T65"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "提示在一定剂量范围内，格列哇喹降糖作用呈剂量依赖性。",
          "start_idx": 120,
          "end_idx": 146,
          "entities": [
            {
              "entity_id": "T72",
              "entity": "格列哇喹",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "12",
      "paragraph": "2.格列喹酮联合治疗降糖有效性及安全性",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.格列喹酮联合治疗降糖有效性及安全性",
          "start_idx": 0,
          "end_idx": 19,
          "entities": [
            {
              "entity_id": "T73",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "13",
      "paragraph": "(1)格列喹酮与二甲双胍联合：一项多中心、随机、开放、平行分组对照研究显示：格列喹酮在单药和(或)联合治疗失败的2型糖尿病患者中与二甲双胍联合治疗14周后，平均HbA1c下降1.7%，HbA1c<6.5%及HbA1c<7.0%的达标率分别为25.71%及42.86%，均高于阿卡波糖联合二甲双胍组；格列喹酮组对PPG降低幅度达4.75mmol/L，是阿卡波糖组的2倍以上：对FPG降低度为1.0mmol/L。此外，格列喹酮组可改善胰岛素抵抗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(1)格列喹酮与二甲双胍联合：一项多中心、随机、开放、平行分组对照研究显示：格列喹酮在单药和(或)联合治疗失败的2型糖尿病患者中与二甲双胍联合治疗14周后，平均HbA1c下降1.7%，HbA1c<6.5%及HbA1c<7.0%的达标率分别为25.71%及42.86%，均高于阿卡波糖联合二甲双胍组；格列喹酮组对PPG降低幅度达4.75mmol/L，是阿卡波糖组的2倍以上：对FPG降低度为1.0mmol/L。",
          "start_idx": 0,
          "end_idx": 204,
          "entities": [
            {
              "entity_id": "T74",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7
            },
            {
              "entity_id": "T75",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T76",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 38,
              "end_idx": 42
            },
            {
              "entity_id": "T77",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 56,
              "end_idx": 61
            },
            {
              "entity_id": "T78",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 56,
              "end_idx": 58
            },
            {
              "entity_id": "T79",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T80",
              "entity": "14周后",
              "entity_type": "Duration",
              "start_idx": 73,
              "end_idx": 77
            },
            {
              "entity_id": "T81",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 80,
              "end_idx": 85
            },
            {
              "entity_id": "T82",
              "entity": "下降1.7%",
              "entity_type": "Test_Value",
              "start_idx": 85,
              "end_idx": 91
            },
            {
              "entity_id": "T83",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 92,
              "end_idx": 97
            },
            {
              "entity_id": "T84",
              "entity": "<6.5%",
              "entity_type": "Test_Value",
              "start_idx": 97,
              "end_idx": 102
            },
            {
              "entity_id": "T85",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 103,
              "end_idx": 108
            },
            {
              "entity_id": "T86",
              "entity": "<7.0%",
              "entity_type": "Test_Value",
              "start_idx": 108,
              "end_idx": 113
            },
            {
              "entity_id": "T87",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 141
            },
            {
              "entity_id": "T88",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 147
            },
            {
              "entity_id": "T89",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 149,
              "end_idx": 153
            },
            {
              "entity_id": "T90",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 155,
              "end_idx": 158
            },
            {
              "entity_id": "T91",
              "entity": "降低幅度达4.75mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 158,
              "end_idx": 173
            },
            {
              "entity_id": "T92",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 175,
              "end_idx": 179
            },
            {
              "entity_id": "T93",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 187,
              "end_idx": 190
            },
            {
              "entity_id": "T94",
              "entity": "降低度为1.0mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 190,
              "end_idx": 203
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R27",
              "head_entity_id": "T74",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R28",
              "head_entity_id": "T75",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R29",
              "head_entity_id": "T80",
              "tail_entity_id": "T76"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R30",
              "head_entity_id": "T78",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R31",
              "head_entity_id": "T81",
              "tail_entity_id": "T77"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R32",
              "head_entity_id": "T80",
              "tail_entity_id": "T79"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "此外，格列喹酮组可改善胰岛素抵抗。",
          "start_idx": 204,
          "end_idx": 221,
          "entities": [
            {
              "entity_id": "T95",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7
            },
            {
              "entity_id": "T96",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 11,
              "end_idx": 16
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "14",
      "paragraph": "(2)格列喹酮与胰岛素联合：格列喹酮与中效胰岛素联合治疗降低患者HbA1c、PPG及FPG的效果优于预混胰岛素组(P<0.05)，同时不增加低血糖发生率。中效胰岛素可以明显改善空腹血糖，但对餐后血糖控制欠佳者，联合格列喹酮治疗可以很好地克服这一问题。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(2)格列喹酮与胰岛素联合：格列喹酮与中效胰岛素联合治疗降低患者HbA1c、PPG及FPG的效果优于预混胰岛素组(P<0.05)，同时不增加低血糖发生率。",
          "start_idx": 0,
          "end_idx": 77,
          "entities": [
            {
              "entity_id": "T97",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7
            },
            {
              "entity_id": "T98",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 11
            },
            {
              "entity_id": "T99",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18
            },
            {
              "entity_id": "T100",
              "entity": "中效胰岛素",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 24
            },
            {
              "entity_id": "T101",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 32,
              "end_idx": 37
            },
            {
              "entity_id": "T102",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 38,
              "end_idx": 41
            },
            {
              "entity_id": "T103",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 42,
              "end_idx": 45
            },
            {
              "entity_id": "T104",
              "entity": "预混胰岛素",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 55
            },
            {
              "entity_id": "T105",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 70,
              "end_idx": 73
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "中效胰岛素可以明显改善空腹血糖，但对餐后血糖控制欠佳者，联合格列喹酮治疗可以很好地克服这一问题。",
          "start_idx": 77,
          "end_idx": 125,
          "entities": [
            {
              "entity_id": "T106",
              "entity": "中效胰岛素",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 5
            },
            {
              "entity_id": "T107",
              "entity": "空腹血糖",
              "entity_type": "Test_items",
              "start_idx": 11,
              "end_idx": 15
            },
            {
              "entity_id": "T108",
              "entity": "餐后血糖",
              "entity_type": "Test_items",
              "start_idx": 18,
              "end_idx": 22
            },
            {
              "entity_id": "T109",
              "entity": "控制欠佳",
              "entity_type": "Test_Value",
              "start_idx": 22,
              "end_idx": 26
            },
            {
              "entity_id": "T110",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 34
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "16",
      "paragraph": "(4)格列喹酮与二肽基肽酶-Ⅳ抑制剂(DPP-4i)联合：格列喹酮与西格列汀联合治疗初诊2型糖尿病患者的研究结果显示：联合用药治疗后患者平均血糖FPG6.5mmol/L、PPG7.3mmol/L、HbA1c6.2%，降糖效果优于单用西格列汀(P<0.01)，无低血糖发生，且能够改善胰岛素抵抗。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(4)格列喹酮与二肽基肽酶-Ⅳ抑制剂(DPP-4i)联合：格列喹酮与西格列汀联合治疗初诊2型糖尿病患者的研究结果显示：联合用药治疗后患者平均血糖FPG6.5mmol/L、PPG7.3mmol/L、HbA1c6.2%，降糖效果优于单用西格列汀(P<0.01)，无低血糖发生，且能够改善胰岛素抵抗。",
          "start_idx": 0,
          "end_idx": 147,
          "entities": [
            {
              "entity_id": "T111",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7
            },
            {
              "entity_id": "T112",
              "entity": "二肽基肽酶-Ⅳ抑制剂(DPP-4i)",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 26
            },
            {
              "entity_id": "T113",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 33
            },
            {
              "entity_id": "T114",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38
            },
            {
              "entity_id": "T115",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 49
            },
            {
              "entity_id": "T116",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 44,
              "end_idx": 46
            },
            {
              "entity_id": "T117",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 72,
              "end_idx": 75
            },
            {
              "entity_id": "T118",
              "entity": "6.5mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 75,
              "end_idx": 84
            },
            {
              "entity_id": "T119",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 85,
              "end_idx": 88
            },
            {
              "entity_id": "T120",
              "entity": "7.3mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 88,
              "end_idx": 97
            },
            {
              "entity_id": "T121",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 98,
              "end_idx": 103
            },
            {
              "entity_id": "T122",
              "entity": "6.2%",
              "entity_type": "Test_Value",
              "start_idx": 103,
              "end_idx": 107
            },
            {
              "entity_id": "T123",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 116,
              "end_idx": 120
            },
            {
              "entity_id": "T124",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 130,
              "end_idx": 133
            },
            {
              "entity_id": "T125",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 141,
              "end_idx": 146
            },
            {
              "entity_id": "T126",
              "entity": "平均血糖",
              "entity_type": "Test_items",
              "start_idx": 68,
              "end_idx": 72
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R33",
              "head_entity_id": "T113",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R34",
              "head_entity_id": "T114",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R35",
              "head_entity_id": "T116",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R36",
              "head_entity_id": "T117",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R37",
              "head_entity_id": "T121",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R38",
              "head_entity_id": "T126",
              "tail_entity_id": "T115"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R39",
              "head_entity_id": "T125",
              "tail_entity_id": "T115"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "17",
      "paragraph": "(5)格列喹酮与噻唑烷二酮类(TZDs)联合：格列喹酮等磺脲类药物与罗格列酮联合应用治疗2型糖尿病患者的研究结果显示，可有效降低HbA1c、PPG及FPG(P<0.05)，改善胰岛素抵抗及高胰岛素血症，且未监测到低血糖发生。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(5)格列喹酮与噻唑烷二酮类(TZDs)联合：格列喹酮等磺脲类药物与罗格列酮联合应用治疗2型糖尿病患者的研究结果显示，可有效降低HbA1c、PPG及FPG(P<0.05)，改善胰岛素抵抗及高胰岛素血症，且未监测到低血糖发生。",
          "start_idx": 0,
          "end_idx": 112,
          "entities": [
            {
              "entity_id": "T127",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7
            },
            {
              "entity_id": "T128",
              "entity": "噻唑烷二酮类(TZDs)",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 20
            },
            {
              "entity_id": "T129",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27
            },
            {
              "entity_id": "T130",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 33
            },
            {
              "entity_id": "T131",
              "entity": "罗格列酮",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38
            },
            {
              "entity_id": "T132",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 49
            },
            {
              "entity_id": "T133",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 44,
              "end_idx": 46
            },
            {
              "entity_id": "T134",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 64,
              "end_idx": 69
            },
            {
              "entity_id": "T135",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 70,
              "end_idx": 73
            },
            {
              "entity_id": "T136",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 74,
              "end_idx": 77
            },
            {
              "entity_id": "T137",
              "entity": "胰岛素抵抗",
              "entity_type": "Pathogenesis",
              "start_idx": 88,
              "end_idx": 93
            },
            {
              "entity_id": "T138",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 106,
              "end_idx": 109
            },
            {
              "entity_id": "T139",
              "entity": "高胰岛素血症",
              "entity_type": "Disease",
              "start_idx": 94,
              "end_idx": 100
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R40",
              "head_entity_id": "T129",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R41",
              "head_entity_id": "T130",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R42",
              "head_entity_id": "T131",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R43",
              "head_entity_id": "T133",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R44",
              "head_entity_id": "T134",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R45",
              "head_entity_id": "T135",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R46",
              "head_entity_id": "T136",
              "tail_entity_id": "T132"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R47",
              "head_entity_id": "T137",
              "tail_entity_id": "T132"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "18",
      "paragraph": "建议：对于应用基础胰岛素或其他口服降糖药不能有效控制血糖的患者，格列喹酮可与多种降糖药物联合使用，通过机制互补增加降糖作用，降低不良反应。一般不推荐与餐时胰岛素或其他促泌剂联用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "建议：对于应用基础胰岛素或其他口服降糖药不能有效控制血糖的患者，格列喹酮可与多种降糖药物联合使用，通过机制互补增加降糖作用，降低不良反应。",
          "start_idx": 0,
          "end_idx": 69,
          "entities": [
            {
              "entity_id": "T140",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 12
            },
            {
              "entity_id": "T141",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 15,
              "end_idx": 17
            },
            {
              "entity_id": "T142",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 26,
              "end_idx": 28
            },
            {
              "entity_id": "T143",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 36
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "一般不推荐与餐时胰岛素或其他促泌剂联用。",
          "start_idx": 69,
          "end_idx": 89,
          "entities": [
            {
              "entity_id": "T144",
              "entity": "餐时胰岛素",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 11
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "19",
      "paragraph": "三、格列喹酮应用于特殊人群",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、格列喹酮应用于特殊人群",
          "start_idx": 0,
          "end_idx": 13,
          "entities": [
            {
              "entity_id": "T145",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "20",
      "paragraph": "1.老年患者",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.老年患者",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "21",
      "paragraph": "对于格列喹酮治疗平均年龄60岁老年患者、近4年半的回顾性分析中，格列喹酮单药及联合治疗1年后，HbA1c下降1.7%，PPG下降6.38mmol/L，FPG下降4.45mmo/L(P<0.01)；另一项针对老年患者的研究显示格列喹酮在降糖的同时可有效改善尿蛋白排泄率(UAE)、β细胞功能指数(HOMA-β)(P<0.001)。以上两项研究的安全性分析显示格列喹酮长期应用低血糖发生人次较少且均为轻度低血糖，进食或调整药物剂量后好转，无低血糖昏迷。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "对于格列喹酮治疗平均年龄60岁老年患者、近4年半的回顾性分析中，格列喹酮单药及联合治疗1年后，HbA1c下降1.7%，PPG下降6.38mmol/L，FPG下降4.45mmo/L(P<0.01)；另一项针对老年患者的研究显示格列喹酮在降糖的同时可有效改善尿蛋白排泄率(UAE)、β细胞功能指数(HOMA-β)(P<0.001)。以上两项研究的安全性分析显示格列喹酮长期应用低血糖发生人次较少且均为轻度低血糖，进食或调整药物剂量后好转，无低血糖昏迷。",
          "start_idx": 0,
          "end_idx": 224,
          "entities": [
            {
              "entity_id": "T146",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T147",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 32,
              "end_idx": 36
            },
            {
              "entity_id": "T148",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 52
            },
            {
              "entity_id": "T149",
              "entity": "下降1.7%",
              "entity_type": "Test_Value",
              "start_idx": 52,
              "end_idx": 58
            },
            {
              "entity_id": "T150",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 59,
              "end_idx": 62
            },
            {
              "entity_id": "T151",
              "entity": "下降6.38mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 62,
              "end_idx": 74
            },
            {
              "entity_id": "T152",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 75,
              "end_idx": 78
            },
            {
              "entity_id": "T153",
              "entity": "下降4.45mmo/L",
              "entity_type": "Test_Value",
              "start_idx": 78,
              "end_idx": 89
            },
            {
              "entity_id": "T154",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 112,
              "end_idx": 116
            },
            {
              "entity_id": "T155",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 178,
              "end_idx": 182
            },
            {
              "entity_id": "T156",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 186,
              "end_idx": 189
            },
            {
              "entity_id": "T157",
              "entity": "轻度",
              "entity_type": "Level",
              "start_idx": 198,
              "end_idx": 200
            },
            {
              "entity_id": "T158",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 200,
              "end_idx": 203
            },
            {
              "entity_id": "T159",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 218,
              "end_idx": 221
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R48",
              "head_entity_id": "T156",
              "tail_entity_id": "T155"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "22",
      "paragraph": "建议：格列喹酮治疗老年2型糖尿病患者低血糖发生率较低，且调整剂量方便，推荐作为老年2型糖尿病患者磺脲类药物的优先选择之一。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "建议：格列喹酮治疗老年2型糖尿病患者低血糖发生率较低，且调整剂量方便，推荐作为老年2型糖尿病患者磺脲类药物的优先选择之一。",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T160",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7
            },
            {
              "entity_id": "T161",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16
            },
            {
              "entity_id": "T162",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13
            },
            {
              "entity_id": "T163",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 18,
              "end_idx": 21
            },
            {
              "entity_id": "T164",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 46
            },
            {
              "entity_id": "T165",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 41,
              "end_idx": 43
            },
            {
              "entity_id": "T166",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 48,
              "end_idx": 53
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R49",
              "head_entity_id": "T160",
              "tail_entity_id": "T161"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R50",
              "head_entity_id": "T163",
              "tail_entity_id": "T160"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R51",
              "head_entity_id": "T162",
              "tail_entity_id": "T161"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R52",
              "head_entity_id": "T165",
              "tail_entity_id": "T164"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "23",
      "paragraph": "2.慢性肾病(CKD)1~5期患者",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.慢性肾病(CKD)1~5期患者",
          "start_idx": 0,
          "end_idx": 17,
          "entities": [
            {
              "entity_id": "T167",
              "entity": "慢性肾病(CKD)",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 11
            },
            {
              "entity_id": "T168",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 4,
              "end_idx": 5
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R53",
              "head_entity_id": "T168",
              "tail_entity_id": "T167"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "24",
      "paragraph": "老年男性2型糖尿病早期肾病患者[尿白蛋白/肌酐比值(ACR)≥30μg/mg，血肌酐(SCr)<177.8μmol/L]经格列喹酮治疗2个月后血糖各指标显著下降，研究结果显示不升高患者尿氮素(BUN)、SCr、ACR。甚至UAE明显降低，SCr水平呈下降趋势，内皮素(ET)、血栓因子2(TXB2)降低，一氧化氮(NO)浓度、前列腺素Flα(PGFlα)升高，意味着格列喹酮通过减少血小板聚集，改善肾血管收缩状态，纠正缺血和炎症，增加肾血流量，实现肾功能改善作用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "老年男性2型糖尿病早期肾病患者[尿白蛋白/肌酐比值(ACR)≥30μg/mg，血肌酐(SCr)<177.8μmol/L]经格列喹酮治疗2个月后血糖各指标显著下降，研究结果显示不升高患者尿氮素(BUN)、SCr、ACR。",
          "start_idx": 0,
          "end_idx": 109,
          "entities": [
            {
              "entity_id": "T169",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T170",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 4,
              "end_idx": 6
            },
            {
              "entity_id": "T171",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 13
            },
            {
              "entity_id": "T172",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 11,
              "end_idx": 12
            },
            {
              "entity_id": "T173",
              "entity": "尿白蛋白/肌酐比值(ACR)",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 30
            },
            {
              "entity_id": "T174",
              "entity": "≥30μg/mg",
              "entity_type": "Test_Value",
              "start_idx": 30,
              "end_idx": 38
            },
            {
              "entity_id": "T175",
              "entity": "血肌酐(SCr)",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 47
            },
            {
              "entity_id": "T176",
              "entity": "<177.8μmol/L]",
              "entity_type": "Test_Value",
              "start_idx": 47,
              "end_idx": 60
            },
            {
              "entity_id": "T177",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 65
            },
            {
              "entity_id": "T178",
              "entity": "2个月后",
              "entity_type": "Duration",
              "start_idx": 67,
              "end_idx": 71
            },
            {
              "entity_id": "T179",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 73
            },
            {
              "entity_id": "T180",
              "entity": "下降",
              "entity_type": "Test_Value",
              "start_idx": 78,
              "end_idx": 80
            },
            {
              "entity_id": "T181",
              "entity": "尿氮素(BUN)",
              "entity_type": "Test_items",
              "start_idx": 92,
              "end_idx": 100
            },
            {
              "entity_id": "T182",
              "entity": "SCr",
              "entity_type": "Test_items",
              "start_idx": 101,
              "end_idx": 104
            },
            {
              "entity_id": "T183",
              "entity": "ACR",
              "entity_type": "Test_items",
              "start_idx": 105,
              "end_idx": 108
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R54",
              "head_entity_id": "T170",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R55",
              "head_entity_id": "T173",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R56",
              "head_entity_id": "T175",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R57",
              "head_entity_id": "T179",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R58",
              "head_entity_id": "T177",
              "tail_entity_id": "T169"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R59",
              "head_entity_id": "T172",
              "tail_entity_id": "T171"
            },
            {
              "relation_type": "Duration_Drug",
              "relation_id": "R60",
              "head_entity_id": "T178",
              "tail_entity_id": "T177"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "甚至UAE明显降低，SCr水平呈下降趋势，内皮素(ET)、血栓因子2(TXB2)降低，一氧化氮(NO)浓度、前列腺素Flα(PGFlα)升高，意味着格列喹酮通过减少血小板聚集，改善肾血管收缩状态，纠正缺血和炎症，增加肾血流量，实现肾功能改善作用。",
          "start_idx": 109,
          "end_idx": 232,
          "entities": [
            {
              "entity_id": "T184",
              "entity": "SCr",
              "entity_type": "Test_items",
              "start_idx": 10,
              "end_idx": 13
            },
            {
              "entity_id": "T185",
              "entity": "下降",
              "entity_type": "Test_Value",
              "start_idx": 16,
              "end_idx": 18
            },
            {
              "entity_id": "T186",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 7,
              "end_idx": 9
            },
            {
              "entity_id": "T187",
              "entity": "UAE",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 5
            },
            {
              "entity_id": "T188",
              "entity": "内皮素(ET)",
              "entity_type": "Test_items",
              "start_idx": 21,
              "end_idx": 28
            },
            {
              "entity_id": "T189",
              "entity": "血栓因子2(TXB2)",
              "entity_type": "Test_items",
              "start_idx": 29,
              "end_idx": 40
            },
            {
              "entity_id": "T190",
              "entity": "降低",
              "entity_type": "Test_Value",
              "start_idx": 40,
              "end_idx": 42
            },
            {
              "entity_id": "T191",
              "entity": "一氧化氮(NO)浓度",
              "entity_type": "Test_items",
              "start_idx": 43,
              "end_idx": 53
            },
            {
              "entity_id": "T192",
              "entity": "前列腺素Flα(PGFlα)",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 68
            },
            {
              "entity_id": "T193",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 68,
              "end_idx": 70
            },
            {
              "entity_id": "T194",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 74,
              "end_idx": 78
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "26",
      "paragraph": "四、总结",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "四、总结",
          "start_idx": 0,
          "end_idx": 4,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "27",
      "paragraph": "格列喹酮是具有肾脏保护作用的胰岛素促泌剂，降糖效果明确，低血糖风险低，不影响体重。单药治疗可全面降糖，亦可与其他非胰岛素促泌剂广泛联合，剂量调整方便，利于个体化治疗，价格合理。主要适用人群为2型糖尿病患者，包括：PPG升高为主的2型糖尿病患者、老年患者和CKD各期患者。由此，格列喹酮可作为中国2型糖尿病患者降糖治疗的一线用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "格列喹酮是具有肾脏保护作用的胰岛素促泌剂，降糖效果明确，低血糖风险低，不影响体重。单药治疗可全面降糖，亦可与其他非胰岛素促泌剂广泛联合，剂量调整方便，利于个体化治疗，价格合理。主要适用人群为2型糖尿病患者，包括：PPG升高为主的2型糖尿病患者、老年患者和CKD各期患者。由此，格列喹酮可作为中国2型糖尿病患者降糖治疗的一线用药。",
          "start_idx": 0,
          "end_idx": 164,
          "entities": [
            {
              "entity_id": "T195",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T196",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 20
            },
            {
              "entity_id": "T197",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 28,
              "end_idx": 31
            },
            {
              "entity_id": "T198",
              "entity": "胰岛素促泌剂",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 63
            },
            {
              "entity_id": "T199",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 100
            },
            {
              "entity_id": "T200",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 95,
              "end_idx": 97
            },
            {
              "entity_id": "T201",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 106,
              "end_idx": 109
            },
            {
              "entity_id": "T202",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 109,
              "end_idx": 111
            },
            {
              "entity_id": "T203",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 119
            },
            {
              "entity_id": "T204",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 114,
              "end_idx": 116
            },
            {
              "entity_id": "T205",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 130
            },
            {
              "entity_id": "T206",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 138,
              "end_idx": 142
            },
            {
              "entity_id": "T207",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 147,
              "end_idx": 152
            },
            {
              "entity_id": "T208",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 147,
              "end_idx": 149
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R61",
              "head_entity_id": "T197",
              "tail_entity_id": "T195"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R62",
              "head_entity_id": "T200",
              "tail_entity_id": "T199"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R63",
              "head_entity_id": "T201",
              "tail_entity_id": "T199"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R64",
              "head_entity_id": "T204",
              "tail_entity_id": "T203"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R65",
              "head_entity_id": "T206",
              "tail_entity_id": "T207"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R66",
              "head_entity_id": "T208",
              "tail_entity_id": "T207"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "25",
      "paragraph": "建议：2015年《2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识(2015)》建议格列喹酮在2型糖尿病合并CKD1~3b期(GFR≥30ml/min)患者中可用，GFR<60ml/min时只有格列喹酮是唯一无需调整剂量的口服磺脲类降糖药；2010年《美国综合临床肾脏病学》推荐格列喹酮在CKD~-5期全程均可使用；2015年欧洲肾脏最佳临床实践(European Renal Best Practice，ERBP)颁布了《糖尿病合并慢性肾脏病3b期或以上(DM-CKD3b~5)患者的诊疗指南》，建议格列喹酮用于CKD1~5期，全程均不需要剂量调整；格列喹酮可有效降低蛋白尿水平，延缓或逆转糖尿病肾病的进一步进展；格列喹酮在老年2型糖尿病合并肾病患者中降糖安全有效。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "建议：2015年《2型糖尿病合并慢性肾脏病口服降糖药用药原则中国专家共识(2015)》建议格列喹酮在2型糖尿病合并CKD1~3b期(GFR≥30ml/min)患者中可用，GFR<60ml/min时只有格列喹酮是唯一无需调整剂量的口服磺脲类降糖药；2010年《美国综合临床肾脏病学》推荐格列喹酮在CKD~-5期全程均可使用；2015年欧洲肾脏最佳临床实践(European Renal Best Practice，ERBP)颁布了《糖尿病合并慢性肾脏病3b期或以上(DM-CKD3b~5)患者的诊疗指南》，建议格列喹酮用于CKD1~5期，全程均不需要剂量调整；格列喹酮可有效降低蛋白尿水平，延缓或逆转糖尿病肾病的进一步进展；格列喹酮在老年2型糖尿病合并肾病患者中降糖安全有效。",
          "start_idx": 0,
          "end_idx": 337,
          "entities": [
            {
              "entity_id": "T209",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 9,
              "end_idx": 14
            },
            {
              "entity_id": "T210",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 9,
              "end_idx": 11
            },
            {
              "entity_id": "T211",
              "entity": "慢性肾脏病",
              "entity_type": "Disease",
              "start_idx": 16,
              "end_idx": 21
            },
            {
              "entity_id": "T212",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 18,
              "end_idx": 20
            },
            {
              "entity_id": "T213",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 21,
              "end_idx": 23
            },
            {
              "entity_id": "T214",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 45,
              "end_idx": 49
            },
            {
              "entity_id": "T215",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 55
            },
            {
              "entity_id": "T216",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 50,
              "end_idx": 52
            },
            {
              "entity_id": "T217",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 60
            },
            {
              "entity_id": "T218",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 104
            },
            {
              "entity_id": "T219",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 114,
              "end_idx": 116
            },
            {
              "entity_id": "T220",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 116,
              "end_idx": 119
            },
            {
              "entity_id": "T221",
              "entity": "肾脏病",
              "entity_type": "Disease",
              "start_idx": 135,
              "end_idx": 138
            },
            {
              "entity_id": "T222",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 135,
              "end_idx": 137
            },
            {
              "entity_id": "T223",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 142,
              "end_idx": 146
            },
            {
              "entity_id": "T224",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 147,
              "end_idx": 150
            },
            {
              "entity_id": "T225",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 215,
              "end_idx": 218
            },
            {
              "entity_id": "T226",
              "entity": "慢性肾脏病",
              "entity_type": "Disease",
              "start_idx": 220,
              "end_idx": 225
            },
            {
              "entity_id": "T227",
              "entity": "DM",
              "entity_type": "Disease",
              "start_idx": 232,
              "end_idx": 234
            },
            {
              "entity_id": "T228",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 235,
              "end_idx": 238
            },
            {
              "entity_id": "T229",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 254,
              "end_idx": 258
            },
            {
              "entity_id": "T230",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 260,
              "end_idx": 263
            },
            {
              "entity_id": "T231",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 279,
              "end_idx": 283
            },
            {
              "entity_id": "T232",
              "entity": "糖尿病肾病",
              "entity_type": "Disease",
              "start_idx": 299,
              "end_idx": 304
            },
            {
              "entity_id": "T233",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 311,
              "end_idx": 315
            },
            {
              "entity_id": "T234",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 318,
              "end_idx": 323
            },
            {
              "entity_id": "T235",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 318,
              "end_idx": 320
            },
            {
              "entity_id": "T236",
              "entity": "肾病",
              "entity_type": "Disease",
              "start_idx": 325,
              "end_idx": 327
            },
            {
              "entity_id": "T237",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 325,
              "end_idx": 326
            },
            {
              "entity_id": "T238",
              "entity": "肾脏",
              "entity_type": "Anatomy",
              "start_idx": 222,
              "end_idx": 224
            },
            {
              "entity_id": "T239",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 302,
              "end_idx": 303
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R67",
              "head_entity_id": "T210",
              "tail_entity_id": "T209"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R68",
              "head_entity_id": "T214",
              "tail_entity_id": "T215"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R69",
              "head_entity_id": "T216",
              "tail_entity_id": "T215"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R70",
              "head_entity_id": "T219",
              "tail_entity_id": "T220"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R71",
              "head_entity_id": "T222",
              "tail_entity_id": "T221"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R72",
              "head_entity_id": "T223",
              "tail_entity_id": "T221"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R73",
              "head_entity_id": "T238",
              "tail_entity_id": "T226"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R74",
              "head_entity_id": "T231",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R75",
              "head_entity_id": "T239",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R76",
              "head_entity_id": "T233",
              "tail_entity_id": "T234"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R77",
              "head_entity_id": "T235",
              "tail_entity_id": "T234"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R78",
              "head_entity_id": "T237",
              "tail_entity_id": "T236"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "15",
      "paragraph": "(3)格列喹酮与α-糖苷酶抑制剂联合：格列喹酮与阿卡波糖联合治疗老年2型糖尿病患者的研究结果显示：联合用药对PPG及FPG的降幅均大于单用阿卡波糖，同时由于药物剂量减少，胃肠道不适等不良反应发生率明显降低，且无一例出现低血糖反应。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "(3)格列喹酮与α-糖苷酶抑制剂联合：格列喹酮与阿卡波糖联合治疗老年2型糖尿病患者的研究结果显示：联合用药对PPG及FPG的降幅均大于单用阿卡波糖，同时由于药物剂量减少，胃肠道不适等不良反应发生率明显降低，且无一例出现低血糖反应。",
          "start_idx": 0,
          "end_idx": 115,
          "entities": [
            {
              "entity_id": "T240",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 3,
              "end_idx": 7
            },
            {
              "entity_id": "T241",
              "entity": "α-糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 16
            },
            {
              "entity_id": "T242",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23
            },
            {
              "entity_id": "T243",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28
            },
            {
              "entity_id": "T244",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 34,
              "end_idx": 39
            },
            {
              "entity_id": "T245",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 34,
              "end_idx": 36
            },
            {
              "entity_id": "T246",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 54,
              "end_idx": 57
            },
            {
              "entity_id": "T247",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 58,
              "end_idx": 61
            },
            {
              "entity_id": "T248",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 69,
              "end_idx": 73
            },
            {
              "entity_id": "T249",
              "entity": "胃肠道不适",
              "entity_type": "ADE",
              "start_idx": 85,
              "end_idx": 90
            },
            {
              "entity_id": "T250",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 109,
              "end_idx": 112
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R79",
              "head_entity_id": "T242",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R80",
              "head_entity_id": "T249",
              "tail_entity_id": "T242"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R81",
              "head_entity_id": "T243",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R82",
              "head_entity_id": "T249",
              "tail_entity_id": "T243"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R83",
              "head_entity_id": "T245",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R84",
              "head_entity_id": "T246",
              "tail_entity_id": "T244"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R85",
              "head_entity_id": "T247",
              "tail_entity_id": "T244"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "11",
      "paragraph": "建议：(1)格列喹酮对2型糖尿病患者各项血糖指标均有很好的控制作用，可作为2型糖尿病降糖选择的一线用药之一；对于主要以PPG升高为主的，或新发2型糖尿病患者，格列喹酮可作为磺脲类药物的优先选择。(2)格列喹酮临床处方剂量范围为15~180mg/d，根据长期临床使用经验，在综合考虑患者耐受程度及经济情况等条件的前提下，推荐使用格列喹酮单药治疗90mg/d(30mg，Tid)能够尽快使血糖达标；若患者控糖效果不理想，可综合考虑患者基本情况增加临床处方剂量，推荐最大剂量180mg/d(60mg，Tid)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "建议：(1)格列喹酮对2型糖尿病患者各项血糖指标均有很好的控制作用，可作为2型糖尿病降糖选择的一线用药之一；对于主要以PPG升高为主的，或新发2型糖尿病患者，格列喹酮可作为磺脲类药物的优先选择。(2)格列喹酮临床处方剂量范围为15~180mg/d，根据长期临床使用经验，在综合考虑患者耐受程度及经济情况等条件的前提下，推荐使用格列喹酮单药治疗90mg/d(30mg，Tid)能够尽快使血糖达标；若患者控糖效果不理想，可综合考虑患者基本情况增加临床处方剂量，推荐最大剂量180mg/d(60mg，Tid)。",
          "start_idx": 0,
          "end_idx": 252,
          "entities": [
            {
              "entity_id": "T251",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T252",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 16
            },
            {
              "entity_id": "T253",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13
            },
            {
              "entity_id": "T254",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 20,
              "end_idx": 22
            },
            {
              "entity_id": "T255",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 42
            },
            {
              "entity_id": "T256",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 37,
              "end_idx": 39
            },
            {
              "entity_id": "T257",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 59,
              "end_idx": 62
            },
            {
              "entity_id": "T258",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 62,
              "end_idx": 64
            },
            {
              "entity_id": "T259",
              "entity": "2型糖尿病",
              "entity_type": "Disease",
              "start_idx": 71,
              "end_idx": 76
            },
            {
              "entity_id": "T260",
              "entity": "2型",
              "entity_type": "Class",
              "start_idx": 71,
              "end_idx": 73
            },
            {
              "entity_id": "T261",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 79,
              "end_idx": 83
            },
            {
              "entity_id": "T262",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 91
            },
            {
              "entity_id": "T263",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 104
            },
            {
              "entity_id": "T264",
              "entity": "15~180mg/d",
              "entity_type": "Amount",
              "start_idx": 113,
              "end_idx": 123
            },
            {
              "entity_id": "T265",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167
            },
            {
              "entity_id": "T266",
              "entity": "90mg/d(30mg，Tid)",
              "entity_type": "Amount",
              "start_idx": 171,
              "end_idx": 187
            },
            {
              "entity_id": "T267",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 192,
              "end_idx": 194
            },
            {
              "entity_id": "T268",
              "entity": "达标",
              "entity_type": "Test_Value",
              "start_idx": 194,
              "end_idx": 196
            },
            {
              "entity_id": "T269",
              "entity": "180mg/d(60mg，Tid)",
              "entity_type": "Amount",
              "start_idx": 234,
              "end_idx": 251
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R86",
              "head_entity_id": "T251",
              "tail_entity_id": "T252"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R87",
              "head_entity_id": "T253",
              "tail_entity_id": "T252"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R88",
              "head_entity_id": "T254",
              "tail_entity_id": "T252"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R89",
              "head_entity_id": "T256",
              "tail_entity_id": "T255"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R90",
              "head_entity_id": "T257",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R91",
              "head_entity_id": "T260",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R92",
              "head_entity_id": "T261",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R93",
              "head_entity_id": "T262",
              "tail_entity_id": "T259"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R94",
              "head_entity_id": "T264",
              "tail_entity_id": "T263"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R95",
              "head_entity_id": "T266",
              "tail_entity_id": "T265"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R96",
              "head_entity_id": "T269",
              "tail_entity_id": "T265"
            }
          ]
        }
      ]
    }
  ]
}